Choose a folder
DISCOVER Scientific Bulletin
All the latest exciting updates on the progress of the global DISCOVER study will soon be made available to investigators in a new Scientific Bulletin. The newsletter will be distributed via email to all the DISCOVER investigators, and will provide the latest study news, as well as highlighting relevant recent advances in the field of type 2 diabetes.
The first edition of the Scientific Bulletin will feature an article by Professor Antonio Nicolucci – a key member of the DISCOVER Scientific Committee – about a recent random-effects network meta-analysis that has been undertaken to make indirect comparisons of the efficacy and safety of various pharmacological treatments for type 2 diabetes. The analysis, authored by Palmer et al. and published in JAMA in July 2016, presents the results of 301 randomized clinical trials of glucose-lowering agents (including insulin) with a duration of at least 24 weeks using a primary outcome measure of cardiovascular mortality. The findings support the recommendation of the American Diabetes Association (ADA) that metformin monotherapy should be used as initial treatment for patients with type 2 diabetes, as well as corroborating ADA guidance on the selection of subsequent therapies. Professor Nicolucci will review the results of the analysis in his article and discuss how studies such as DISCOVER can help to complement the JAMA paper findings.
This edition will also include an update on the progress of DISCOVER from Javier Cid, the scientific lead for this study, plus an overview of plans for publication of baseline data. Recruitment has been an overwhelming success with more than 16 000 patients enrolled, and nearly all of them have complete case report forms and patient-reported outcome questionnaires. The focus is now to build on these successes and ensure patient retention during the 3-year follow-up period.
Availability of baseline data means that abstracts can be developed for submission to the 77th Scientific Sessions of the ADA to be held on 9–13 June 2017 in San Diego, CA, USA. Proposed topics for abstracts include patient characteristics, differences in glycated haemoglobin (HbA1c) control between participating countries, the prevalence of microvascular and macrovascular complications, and global variations in factors likely to influence treatment decisions in patients with type 2 diabetes. Once the DISCOVER data have been fully scrutinized, and subanalyses have been identified and performed, further abstracts can be developed for submission to the 53rd European Association for the Study of Diabetes Annual Meeting on 11–15 September 2017 in Lisbon, Portugal. Suggestions for country-specific analyses and publications are invited and can be submitted via an online platform. Details of how to submit proposals will be made available shortly, so please keep visiting the DISCOVER website for updates.